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Introduction
Despite recent progress in understanding of its patho-
genesis, Graves' ophthalmopathy (GO) remains 
a pathogenetic enigma and a therapeutic dilemma
[1,2]. GO is currently characterized as an autoimmune
infiltration of the orbital connective tissue and/or
extraocular muscles predominantly by activated T cells
together with some B cells, plasmocytes and masto-
cytes. The thyrotropin receptor (TSHR) autoantigen is
the probable culprit involved in GO [3,4]. Both anti-
TSHR antibodies (TSHRab) and homing of autoreac-
tive T lymphocytes can initiate or perpetuate the
inflammatory process of retrobulbar tissues in GO
[5,6]. T lymphocytes which infiltrate retroocular tis-
sues, by releasing cytokines act upon retroocular
fibroblasts to stimulate cells proliferation [7]. T cells
play a direct role promoting adipogenesis, gly-
cosaminoglycan synthesis and expression of
immunomodulatory proteins within the orbit [3]. The
process of autoreactive T lymphocytes recruitment
may be facilitated by either circulating or locally pro-
duced adhesion molecules [3], the expression of which
may be induced by cytokines [6] and be related to the
activity of the disease [8,9]. Adhesion molecules play
a central role not only in T lymphocyte activation and
localization but also T cell costimulation and various
effector-target cell functions at the inflammatory sites,
which result in amplification of the cellular immune
process in active GO [6]. In our previous study serum
L-selectin and Intercellular Adhesion Molecule-1
(ICAM-1) were found to be elevated in patients with
active GO, suggesting enhanced T cell recruitment
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[10]. Moreover the ICAM-1 gene polymorphism could
influence the intensity and duration of the autoimmu-
nity process and the infiltration of orbital tissues [11]. 
The aim of the present study was to evaluate the
percentage of L-selectin+ (CD62L+) and ICAM-1+
(CD54+) expressing CD4+/CD8+ T lymphocytes in
patients with Graves' disease and to assess if these esti-
mations could be helpful as markers of active ophthal-
mopathy.        
Material and Methods
The study was carried out in three groups comprising a total of 25
patients from Outpatient Clinic of the Department of Endocrinolo-
gy, Diabetology and Internal Diseases, Medical University of Bia-
lystok 
All patients were examined by the same clinician, who was
blinded for the TRSHAb data and who assessed the following oph-
thalmological parameters: visual acuity, lid width, downward
movement of the lids (in millimeters), proptosis (in millimeters),
inflammatory signs (redness and swelling of lids and conjunctiva),
and eye motility. In case of reduced visual acuity, the cornea was
stained with fluorescein, and if slit lamp and fundus examination
revealed normal anatomical conditions, visual evoked potentials
were done to examine optic nerve function.
Grouping of patients. The eye signs of GO were classified
according to Clinical Activity Score (CAS) classification and
NOSPECS amended by EUGOGO [12]: 1) active disease – CAS
equal to or greater than 4 and/or NOSPECS equal to or greater than
5 (marked symptoms of GO); 2) and 3) inactive disease, CAS less
than 4 and NOSPECS less than 5 (mild symptoms of GO) or no
signs of ophthalmopathy and different thyroid status (hyperthyroid,
euthyroid).
1) 8 patients with clinical symptoms of ophthalmopathy (GO)
(5 females and 3 males, mean age 41,4±11,5 years). All the GO
patients presented a Clinical Activity Score of eye changes (CAS)
> 3, anamnesis of GO≤1 year, were euthyroid with thiamazol. The
euthyroid state was confirmed by thyrotropin and free thyroxin
estimation. They had never been treated with corticosteroids or
other immunosuppressive drugs.
2) 9 patients with hyperthyroid Graves' disease without symp-
toms of active ophthalmopathy (GDtox) (7 females and 2 males,
mean age 40,2±11,6 years) with a duration of the disease from 3-
12 months. Hyperthyroidism was confirmed by thyrotropin and
free thyroxin estimation.
3) 8 patients with euthyroid Graves' disease without symptoms
of active ophthalmopathy (GDeu) (7 females and 2 males, mean
age 42,4±11,2 years) with a duration of the disease from 3-12
months. Patients in this group were euthyroid before and during the
study and euthyreoidism was confirmed TSH and free thyroxin
determination.
The control group (ctrl) consisted of 15 healthy volunteers (14
females and 6 males, aged 22-40 years) who had neither a family
history of Graves' disease nor other autoimmune diseases. No
acute infections were observed in the GO, GD and control subjects
3 weeks prior to the study. 
Written informed consent was obtained and the protocol for the
study was approved by the Ethics Committee of Medical Universi-
ty of Bialystok.
Flow cytometric analysis. Between 7.30 and 8.30 a.m. fasting
peripheral venous blood samples were obtained in collection tubes
containing ethylenediaminetetraacetic acid stored at room temper-
ature for no longer than 2 hours before staining and CD phenotyp-
ing. A complete blood cell count, including an automated differen-
tial count, was performed used Coulter MAXM ® counter. Briefly,
100 μL of whole blood was stained with 10 μL of the following
three-colour monoclonal antibodies directly conjugated to activat-
ed peridinin-chlorophyll-protein complex (PerCP) and fluorescein
isotiocyanate (FITC) or phycoerythrin (PE): CD4-PerCP, CD8-
PerCP, CD62L-FITC, CD54-PE. After incubation at room temper-
ature for 20 minutes, the samples were than processed with a 35-
second cycle on a rapid no-wash whole blood lysis work station
(Beckman Coulter). A minimum of 104 cells were analyzed by
Cytomics FC 500 flow cytometer (Beckman Culter). The peripher-
al blood lymphocytes were gated by forward-scattering and side-
ward-scattering characteristics. The percentage of CD4+PerCP
lymphocytes expressing CD54+PE and CD62L+FITC and then the
percentage of CD8+PerCP lymphocytes expressing CD54+PE and
CD62L+FITC were analyzed and calculated by the software. For
each mAb isotype, specific negative control was used. The per-
centage of positive cells was determined by setting the lower limit
over the non-specific fluorescence with suitable controls. 
TSHRab analysis. All the sera were kept frozen at -70°C until
used. The levels of serum TSH receptor antibodies (TSHRab) were
determined by the second-generation radioimmuno assay using
human recombinant TSH receptor (DYNOtest TRAK human,
BRAHMS, Berlin, Germany): sensivity 0.3 IU/l; mean inter-assay
precision (VC) 7.0%). 
Statistical analysis. The statistical significance was estimated by
the Mann-Whitney U-test. Spearman's test was performed to eval-
uate the relationships between variables. A p value of less than 0.05
was considered statistically significant. All data were performed
using Statistica 6.0 (StatSoft ®, Tulsa, OK, U.S.A.).
Results
The percentages of T cell subsets in examined groups
are shown as median and interquartile ranges (Table 1,
Fig. 1 and 2). CD4+ and CD8+ values are given in
Table 1.
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Table 1. The median and interquartile range values of CD4+ and CD8+ T lymphocytes' percentage in patients with Graves' ophthalmopa-
thy (GO), hyperthyroid (GDtox) and euthyroid Graves' disease (GDeu) 
The median percentage of CD4+CD62L+ T lympho-
cytes (Fig.1) was significantly higher (p<0.001) in all
studied groups as compared to controls (49.0 (42.5-
58.5)): in GO patients 76.2 (64.7-78.7), in hyperthy-
roid GD 71.0 (67.2-71.9) and in euthyroid GD 76.0
(69.0-83.1). 
We found the median percentage of CD4+CD54+ T
lymphocytes (Fig. 1) significantly higher in GO
patients (p<0.01) 17.0 (11.2-23.5) and in hyperthyroid
GD (p<0.05) 10.0 (8.3-16.0) as compared to controls
5.1 (3.8-6.6). In euthyroid GD patients the median per-
centage of CD4+CD54+ T cells was 11.2 (2.6-18.5). 
The median percentage of CD8+CD62L+ T lympho-
cytes (Fig. 2) was significantly higher (p<0.05) in the
GO group 48.5 (34.5-68.2) as compared to controls
31.0 (27.5-36.5). The median CD8+CD62L+ T lympho-
cytes' percentage in the hyperthyroid GD was 37.0
(32.0-53.0) and in the euthyroid GD was 31.0 (27.4-
34.9). 
We found the median percentage of CD8+CD54+ T
lymphocytes (Fig. 2) significantly elevated in GO
patients (p<0.001) 17.5 (11.3-33.7), in hyperthyroid
GD (p<0.05) 9.7 (6.1-13.0) and in euthyroid GD
(p<0.01) 13.0 (8.4-14.7) as compared to controls 3.2
(2.1-5.1). The significant difference in the median per-
centage of CD8+CD54+ T lymphocytes was also observed
between the GO group and hyperthyroid GD patients.
We found positive correlation between TSHRab
concentration and the percentage of CD8+CD62L+ T
lymphocytes in all studied groups (r=0.39, p<0.05)
(Fig.3) and between TSHRab level and CAS (r=0.77,
p<0.05) (data not shown). 
Discussion
In previous reports the elevated levels of serum
ICAM-1 and L-selectin were demonstrated in patients
with Graves' disease and GO [10,13,14]. Moreover the
analysis of CD62L+ and CD54+ antigen expression on
peripheral mononuclear cells revealed increased per-
centages of L-selectin and ICAM-1 positive cells in
patients with GD before methimazole therapy [15].
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Fig. 1. The median percentage of CD4+CD62L+ and CD4+CD54+ T lymphocytes in patients with Graves' ophthalmopathy (GO), hyperthy-
roid Graves' disease (GDtox), euthyroid Graves' disease (GDeu) compared to controls (ctrl), (whiskers display the interquartile range).
Fig. 2. The median percentage of CD8+CD62L+ and CD8+CD54+ T lymphocytes in patients with Graves' ophthalmopathy (GO), hyperthy-
roid Graves' disease (GDtox), euthyroid Graves' disease (GDeu) compared to controls (ctrl), (whiskers display the interquartile range).
Consistently with these findings we demonstrated the
increased percentage of CD4+CD62L+ T lymphocytes
both in patients with GD and GO. The elevated serum
concentration and enhanced expression on cell surface
can result from increased shedding of CD62L mole-
cule from activated CD4+ T cells and in the conse-
quence reflect the ongoing immune process [10].
Although the percentage of CD4+ T cells was only sig-
nificantly higher in patients with hyperthyroid GD the
percentage of its subset expressing ICAM-1 was con-
siderably increased in GO group. In agreement with
that, the subset of CD4+ T cells was found to predom-
inate in the orbit infiltration in GO [16,17]. After anti-
gen recognition, CD4+ T lymphocytes could secrete
cytokines that amplify the immune reaction by either
activating CD8+ T lymphocytes or autoantibody-pro-
ducing B cells [18]. Th1 cell-mediated immune
response seem to play an important role in the early
GO [19]. In a recent study the percentage of CD4+ T
lymphocytes was higher and the percentage of CD8+ T
cells was lower in both groups of patients with GD and
GO [19]. Our data suggest that the immune reaction in
early GO is probably unique and different from that in
GD without ophthalmopathy (especially with thyro-
toxicosis). Although there is no difference in the per-
centage of CD8+ in patients with GO vs. control there
are considerable shifts in the subpopulations of CD8+
T cells expressing L-selectin and ICAM-1 molecules.
The elevated percentage of these subsets may reflect
the T cell activation into cellular immune response
[18]. The significantly higher percentage of CD8+CD54+
T lymphocytes in patients with GO (not only vs. con-
trol but also vs. hyperthyroid GD) proves evidence for
this notion. 
In GO ICAM-1 is thought to play a key role in
lymphocyte infiltration into the orbit and ICAM-1
antibody produced a concentration dependent inhibi-
tion of the IL-1 alpha-induced adhesion of peripheral
blood mononuclear cells to the orbital fibroblasts
[20]. ICAM-1 serum level was positively correlated
to Clinical Activity Score and was established to be a
good parameter of disease activity in progressive
infiltrative GO [9,13].  An assessment of soluble
forms of both ICAM-1 and L-selectin were found
helpful as prognostic for immunotherapeutic efficacy
during treatment with corticosteroids [10,21].  De
Bellis et al. demonstrated that serial determinations
of ICAM-1 serum levels could help to identify the
subgroup of GD patients prone to develop severe
clinical ophthalmopathy with retroocular connective
inflammation [13]. More recently Wakelkamp et al.
found that the major determinant of soluble ICAM-1
level in GO patients is the severity of their eye dis-
ease [14]. Our data suggest that the evaluation of the
percentage of CD8+CD54+ and CD8+CD62L+ T lympho-
cytes in patients with GO could help to identify those
GD patients who prone to develop active inflamma-
tory ophthalmopathy and need intensive treatment for
GO. The positive correlation of the percentage of
CD8+CD62L+ T lymphocytes and TSHRab seem to
confirm a role of these autoreactive cells in the
autoimmune process in GO.
In conclusion, the increased percentage of
CD8+CD54+ and CD8+CD62L+ T cells in patients with
Graves' ophthalmopathy may be used as a marker of
immune inflammation activity.  Assessment of
CD4+CD62L+ peripheral blood cells can not discrimi-
nate patients with GO though it may become a good
parameter of ongoing autoimmune process in patients
with Graves with and without ophthalmopathy. Never-
theless, since the limitation of the study, our data need
further analysis on larger populations.  
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Fig. 3. The positive correlation
between TSHRab concentration and
the percentage of CD8+CD62L+ T
lymphocytes in all studied groups 
(r= 0.39, p<0.05)
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